Navigation Links
PTC Therapeutics Presents Encouraging Phase 1 Results of its Novel VEGF Inhibitor, PTC299, at 30th Annual San Antonio Breast Cancer Symposium
Date:12/17/2007

- Company Initiates Phase1b/2 Clinical Trial in Breast Cancer -

SAN ANTONIO and SOUTH PLAINFIELD, N.J., Dec. 17 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC), a biopharmaceutical company focused on the discovery, development, and commercialization of small-molecule drugs targeting post-transcriptional control mechanisms announced the presentation of preclinical and Phase 1 data regarding PTC299, its novel, internally discovered, vascular endothelial growth factor (VEGF) inhibitor. PTC299 is an orally bioavailable investigational drug which is designed to inhibit the production of VEGF in tumors, acting upstream of current anti-angiogenic agents that function at the site of the VEGF receptor. The preclinical and clinical data presented today formed the basis for the recent initiation of a Phase 1b/2 clinical trial of PTC299 in patients with advanced breast cancer.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO )

"We are pleased to present these preclinical data on PTC299, which show drug activity in multiple preclinical models of human cancer, including breast cancer," said Langdon Miller, M.D., Chief Medical Officer of PTC Therapeutics, Inc. "Based on the safety profile and pharmacokinetic results from our Phase 1a studies, we are excited to have initiated a Phase 1b/2 trial of PTC299 in patients with advanced breast cancer. Our hope is that PTC299 will offer an active, well-tolerated, and convenient oral therapy for patients with breast cancer and other tumor types."

The data were detailed in a poster presentation at the San Antonio Breast Cancer Symposium entitled, "Preclinical Efficacy in Breast Cancer Xenografts and Phase 1 Results of PTC299, a Novel VEGF Expression Inhibitor," (Poster Number 6082).

In the preclinical studies, PTC299 was administered to mice harboring established human breast tumor xenografts. In these studies,
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Calif. , May 23, 2013 More ... cancer may not benefit from chemotherapy and still have ... the launch of one of the largest sources of ... new website and interactive Facebook page provide recently diagnosed ... they can safely avoid chemotherapy. "We anticipate ...
(Date:5/23/2013)... Calif. , May 23, 2013 Anthem ... program that would have required them to obtain their ... by Consumer Watchdog and Whatley Kallas LLC.  ... Superior Court, alleged that Blue Cross,s mandatory mail order ... threatening their health and privacy. "This settlement ...
(Date:5/23/2013)... Texas , May 23, 2013  Texas, premier ... to deliver doctors the survival tools they need to ... compete in today,s health care marketplace. "I ... will save local practices," said Stephen L. ... Association (TMA). " Texas doctors are ...
Breaking Medicine Technology:Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 2Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 3Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 2Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 3TMA Launches Physician Services Organization for Patient Care 2TMA Launches Physician Services Organization for Patient Care 3TMA Launches Physician Services Organization for Patient Care 4
... Qmed .com , the world,s only 100% ... engine, and central industry resource, today announced a ... ground-breaking detailed reports of industry-related adverse events, ... http://photos.prnewswire.com/prnh/20120423/LA91769LOGO )   (Logo: http://photos.prnewswire.com/prnh/20101214/LA16070LOGO ...
... BEACH, Fla., April 23, 2012  SurgLine International, Inc. ... International, Inc. ("SGLN") and SurgLine, Inc. ("SurgLine") stated ... SurgLine has formed SurgLine MDC Holdings, LLC. ("SMDC"), ... owned subsidiary.  SMDC will be forming  joint-venture opportunities ...
Cached Medicine Technology:Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events 2Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events 3Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events 4SurgLine International, Inc. Launches A Wholly Owned Operating Subsidiary To Pursue Cost Containment Strategies 2
(Date:5/23/2013)... May 23, 2013 Memorial Day Focus ... Chaplains have been a part of the U.S. Military ... like those preceding it, these men and women will ... United States of America. As veterans transition to ... migration to the workplace chaplaincy world. , Marketplace ...
(Date:5/23/2013)... doubt it when a woman harried by hot flashes ... new study published online in Menopause , the ... confirm with objective tests that what these women say ... some studies showed that hot flashes were related to ... even though there was a relationship between hot flashes ...
(Date:5/23/2013)... leading journal Science published an article about ... and an important starting point for further Alzheimer,s research. ... researcher at VIB and KU Leuven in collaboration ... and scientists at Janssen Pharmaceutica, Beerse, also tested ... Their results were different, as were those of two ...
(Date:5/23/2013)... “Talk. They Hear You.” a new national ... talk to children as young as nine years old ... by the Substance Abuse and Mental Health Services Administration ... SAMHSA’s 2013 National Prevention Week—an annual health observance dedicated ... and mental health issues. , SAMHSA’s latest report on ...
(Date:5/23/2013)... PA (PRWEB) May 23, 2013 ... Teaching Site, offering a comprehensive babysitting training course for ... program was developed by Indianapolis pediatrician Dr. Patricia Keener ... the care of an adult sitter who didn’t know ... well-rounded youth development program with a medical basis that ...
Breaking Medicine News(10 mins):Health News:Memorial Day Focus Spotlight on Military Chaplains Transitioning in the Marketplace 2Health News:Memorial Day Focus Spotlight on Military Chaplains Transitioning in the Marketplace 3Health News:New insights contradict promising Alzheimer's research 2Health News:New Campaign to Help Parents Talk to Younger Children About the Dangers of Underage Drinking 2Health News:Susquehanna Health Offers Safe Sitter Course for Tweens and Teens 2Health News:Susquehanna Health Offers Safe Sitter Course for Tweens and Teens 3
... how cocaine corrupts the brain and becomes addictive. These findingsthe ... cocaine rewardwere published in Science on October 15. ... treating those addicted to the drug. Led by ... Neuroscience at Mount Sinai School of Medicine and first author ...
... The US Department of Defense (DOD) has awarded a ... Research and the University of Cincinnati to further develop ... severe brain injury. Management of severe brain trauma ... critical first few hours and days after an injury. ...
... , MONDAY, Oct. 18 (HealthDay News) -- Canadian ... the so-called swine flu -- to be very severe this ... of 50, especially those with chronic health conditions, get immunized ... results of blood tests given to 1,127 people in the ...
... Institute has awarded a $4.37 million grant to Jeffrey ... to advance a recent scientific laboratory discovery into a ... under the American Recovery and Reinvestment Act, will help ... by Toretsky and his team a critical step ...
... Texas (October 18, 2010) The latest colorectal ... Gastroenterology,s (ACG) 75th Annual Scientific meeting in San ... evidence that suggests significant disparity in colorectal cancer ... the first in a series of studies investigating ...
... Antonio, Texas (October 18, 2010) Investment in screening ... 50 and 64, is needed to reduce the costs ... the results of a new study, "Cost-Savings to Medicare ... unveiled today at the American College of Gastroenterology,s (ACG) ...
Cached Medicine News:Health News:Mount Sinai researchers discover why cocaine is so addictive 2Health News:Feinstein Institute to share $5M US Department of Defense grant 2Health News:H1N1 Unlikely to Cause Flu Pandemic in 2010-11: Analysis 2Health News:$4.37 million NCI grant accelerates recent laboratory finding in Ewing's sarcoma 2Health News:$4.37 million NCI grant accelerates recent laboratory finding in Ewing's sarcoma 3Health News:Notable racial disparities in diagnosis, treatment and outcomes of colorectal cancer 2Health News:Notable racial disparities in diagnosis, treatment and outcomes of colorectal cancer 3Health News:Investment in CRC screening targeting pre-medicare population could cut medicare treatment costs 2
... The BD Macro-Vue RPR (Rapid ... and Tear-drop Tests are nontreponemal testing ... syphilis described in A Manual of ... in this manual are the most ...
Rapid Plasma Reagin (RPR) set is a non-treponemal flocculation test that is,used for the qualitative and semi-quantitative determination of reagin,antibodies in serum or plasma from persons with syph...
For use as a quality assurance reagent in assays detecting IgG antibody to mumps virus (mumps IgG), IgG antibody to measles (Rubeola) virus (measles IgG) and IgG antibody to varicella zoster virus (V...
... For use as a ... detecting IgG antibody to Toxoplasma ... to rubella virus (rubella IgG), ... IgG) and IgG antibody to ...
Medicine Products: